These intervention effects on s100A8/A9 and NFκB DNA binding mirror a similar pattern observed in leukocyte proinflammatory gene expression in women with breast cancer participating in the trial of 10-week CBSM, who showed mitigation of the rise in CTRA (which includes five genes relevant for NFκB binding: NFKB1, NFKB2, REL, RELA, and RELB) (Antoni et al. 2016). The gene discussed is NFKB1; the disease is breast carcinoma.